Fulcrum Therapeutics sets retention payments and departure of principal accounting officer
Fulcrum Therapeutics approved cash retention payments for its nine remaining full-time employees, including CEO Alex C. Sapir, CLO Curtis Oltmans and CFO Alan Musso, tied to a change in control or qualifying termination. It also agreed that Vice President, Finance and principal accounting officer Greg Tourangeau will depart, with the date to be agreed, and states the departure is not related to any disagreement on financial or accounting matters.
Key points
- Retention payments: $370,040 for Alex C. Sapir, $195,480 for Curtis Oltmans and $195,200 for Alan Musso, payable in cash upon a change in control or qualifying termination
- Change-in-control benefits extended to remaining employees at Vice President level and above if terminated without cause within six months before a change in control
- Greg Tourangeau, VP Finance and principal accounting officer, agreed on June 10, 2026 to depart; departure date not yet set
- Restructuring follows discontinuation of pociredir development for sickle cell disease, approved by the board on May 31, 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.